Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis

Abstract

Background: The clinical course of multiple sclerosis ranges from benign with little disease progression and minimal disability, to severe disease requiring intensive medical treatment. There are no reliable circulating biomarkers for predicting disease outcome. Co-inhibitory receptors regulate the termination of effective immune responses to infections while limiting autoimmunity and/or immunopathology. Based on this, we studied the potential of circulating co-inhibitory receptor levels as predictive biomarkers of multiple sclerosis outcome. Methods: Co-inhibitory receptor [TIGIT (T cell immunoreceptor with Ig and ITIM domains), TIM-3 (T-cell immunoglobulin and mucin domain–containing 3), LAG-3 (lymphocyte activation gene 3), PD-1 (programmed cell death 1), CTLA-4 (cytotoxic T-lymphocyte–associated protein 4)] expression levels in peripheral blood mononuclear cells (PBMCs) were measured using reverse transcription–PCR in 19 healthy controls and 57 patients with untreated multiple sclerosis. All patients were evaluated for disease outcome and paraclinical measures during the following 9–10 years [progression index, Expanded Disability Status Scale (EDSS) score, number of relapses, number of disease modifying therapies (DMTs), baseline brain magnetic resonance imaging T2 lesion volume, and oligoclonal bands (OCBs)]. Results: Patients had significantly lower TIGIT and LAG-3 levels than the controls ( P < 0.02 and P < 0.04, respectively). TIM-3 levels were significantly lower in patients with high vs. low disability index and in patients with SPMS diagnosis compared to patients who remained in the relapsing stage of the disease at final visit (both, P < 0.02). LAG-3 levels were significantly higher in patients with low disability index vs. non-low disability index multiple sclerosis ( P < 0.05). TIM-3 and LAG-3 expression levels correlated significantly with 1-year progression index ( r 2 = 0.076, P < 0.05; 0.087, P < 0.04, respectively) and EDSS score at final visit ( r 2 = 0.31, P < 0.04; 0.320.088, P < 0.04, respectively). Lower LAG-3 levels were associated with higher DMT switching ( r 2 = 0.67, P < 0.05). Compared to the paraclinical and clinical parameters alone, the combined data of the baseline co-inhibitory receptor expression levels and the paraclinical and clinical parameters were superior for predicting the patients that would progress to secondary progressive multiple sclerosis (SPMS). Interpretation: This is an initial exploration of the utility of CTLA-4, PD-1, TIM-3, LAG-3, and TIGIT expression levels as prognostic indicators in untreated, recently diagnosed multiple sclerosis. Our results support the ...

CD96 Downregulation Promotes the Immune Response of CD4 T Cells and Associates with Ankylosing Spondylitis

“…IRs are a class of negative regulators of TCR signaling pathway. A large number of studies have revealed the correlation between IRs and autoimmune diseases [ 28 , 29 ]; CTLA4 and PD1 were associated with AS [ 9 , 10 ]. Thus, it could be speculated that IRs are involved in the pathogenesis of AS.…”

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases

“…Based on the important roles of co-inhibitory receptors in regulating the termination of immune responses and autoimmunity, Lavon et al initially investigated the potential of co-inhibitory molecules as predictive biomarkers and prognostic indicators of MS (116). In a sample size of 57 MS patients and 19 HCs, lower levels of TIGIT and LAG-3 were found on CD4 + T in patients with MS compared to that of the HCs.…”

Novel Roles of the Tim Family in Immune Regulation and Autoimmune Diseases

“…According to recent studies, the expression levels of Tim-3 on peripheral blood mononuclear cells (PBMCs) from patients with MS help predict the prognosis of the disease. Lower expression levels of Tim-3 on PBMCs are associated with an increased possibility of progression to secondary progressive multiple sclerosis (SPMS), while higher Tim-3 expression levels on PBMCs are associated with a benign prognosis 10 years later (56).…”